NRX Pharmaceuticals, Inc. Operating Cash Flow
NRX Pharmaceuticals, Inc. (NRXP) reported Operating Cash Flow of -$13.17 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-14
- NRX Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$8.88M.
- NRX Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$4.29M.
- NRX Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$3.71M.
- NRX Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$2.89M.
- NRX Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$14.11M.
- NRX Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$10.64M.
- NRX Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$21.66M.
- NRX Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$39.76M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$8.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$13.17M 10-Q · filed 2026-08-14 | -$16.88M derived: sum of 3 quarters · filed 2026-08-14 | -$19.77M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2026-03-31 | -$4.29M 10-Q · filed 2026-05-15 | -$8.01M derived: sum of 2 quarters · filed 2026-05-15 | -$10.90M derived: sum of 3 quarters · filed 2026-05-15 | -$14.93M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-12-31 | -$3.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$6.60M derived: sum of 2 quarters · filed 2026-03-23 | -$10.63M derived: sum of 3 quarters · filed 2026-08-14 | -$14.11M 10-K · filed 2026-03-23 | ||||
| 2025-09-30 | -$2.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$6.92M derived: sum of 2 quarters · filed 2026-08-14 | -$10.40M 10-Q · filed 2025-11-14 | -$12.50M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-06-30 | -$4.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$7.51M 10-Q · filed 2026-08-14 | -$9.61M derived: sum of 3 quarters · filed 2026-08-14 | -$11.91M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-03-31 | -$3.48M 10-Q · filed 2026-05-15 | -$5.58M derived: sum of 2 quarters · filed 2026-05-15 | -$7.88M derived: sum of 3 quarters · filed 2026-05-15 | -$10.45M derived: sum of 4 quarters · filed 2026-05-15 | ||||
| 2024-12-31 | -$2.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$4.40M derived: sum of 2 quarters · filed 2026-03-23 | -$6.97M derived: sum of 3 quarters · filed 2026-03-23 | -$10.64M 10-K · filed 2026-03-23 | ||||
| 2024-09-30 | -$2.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$4.87M derived: sum of 2 quarters · filed 2025-11-14 | -$8.54M 10-Q · filed 2025-11-14 | -$11.73M derived: sum of 4 quarters · filed 2025-11-14 | ||||
| 2024-06-30 | -$2.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-18 | -$6.23M 10-Q · filed 2025-08-18 | -$9.43M derived: sum of 3 quarters · filed 2025-08-18 | -$13.99M derived: sum of 4 quarters · filed 2025-08-18 | ||||
| 2024-03-31 | -$3.67M 10-Q · filed 2025-05-15 | -$6.86M derived: sum of 2 quarters · filed 2025-05-15 | -$11.43M derived: sum of 3 quarters · filed 2025-05-15 | -$19.24M derived: sum of 4 quarters · filed 2025-05-15 | ||||
| 2023-12-31 | -$3.19M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-14 | -$7.76M derived: sum of 2 quarters · filed 2025-03-14 | -$15.57M derived: sum of 3 quarters · filed 2025-03-14 | -$21.66M 10-K · filed 2025-03-14 | ||||
| 2023-09-30 | -$4.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$12.38M derived: sum of 2 quarters · filed 2024-11-14 | -$18.46M 10-Q · filed 2024-11-14 | -$26.78M derived: sum of 4 quarters · filed 2024-11-14 | ||||
| 2023-06-30 | -$7.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$13.90M 10-Q · filed 2024-08-14 | -$22.22M derived: sum of 3 quarters · filed 2024-08-14 | -$28.48M derived: sum of 4 quarters · filed 2024-08-14 | ||||
| 2023-03-31 | -$6.09M 10-Q · filed 2024-05-14 | -$14.41M derived: sum of 2 quarters · filed 2024-05-14 | -$20.67M derived: sum of 3 quarters · filed 2024-05-14 | -$35.46M derived: sum of 4 quarters · filed 2024-05-14 | ||||
| 2022-12-31 | -$8.32M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -$14.58M derived: sum of 2 quarters · filed 2024-03-29 | -$29.38M derived: sum of 3 quarters · filed 2024-03-29 | -$39.76M 10-K · filed 2024-03-29 | ||||
| 2022-09-30 | -$6.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$21.06M derived: sum of 2 quarters · filed 2023-11-14 | -$31.44M 10-Q · filed 2023-11-14 | -$42.72M derived: sum of 4 quarters · filed 2023-11-14 | ||||
| 2022-06-30 | -$14.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$25.17M 10-Q · filed 2023-08-14 | -$36.45M derived: sum of 3 quarters · filed 2023-08-14 | -$48.47M derived: sum of 4 quarters · filed 2023-08-14 | ||||
| 2022-03-31 | -$10.38M 10-Q · filed 2023-05-15 | -$21.66M derived: sum of 2 quarters · filed 2023-05-15 | -$33.67M derived: sum of 3 quarters · filed 2023-05-15 | -$45.07M derived: sum of 4 quarters · filed 2023-05-15 | ||||
| 2021-12-31 | -$11.28M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$23.29M derived: sum of 2 quarters · filed 2023-03-31 | -$34.69M derived: sum of 3 quarters · filed 2023-03-31 | -$37.70M 10-K · filed 2023-03-31 | ||||
| 2021-09-30 | -$12.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$23.41M derived: sum of 2 quarters · filed 2022-11-14 | -$26.42M 10-Q · filed 2022-11-14 | -$26.42M 10-Q · filed 2021-11-15 | -$26.83M derived: sum of 4 quarters · filed 2022-11-14 | |||
| 2021-06-30 | -$11.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$14.41M 10-Q · filed 2022-08-15 | -$14.41M 10-Q · filed 2021-08-16 | -$14.82M derived: sum of 3 quarters · filed 2022-08-15 | -$15.95M derived: sum of 4 quarters · filed 2022-08-15 | |||
| 2021-03-31 | -$3.02M 10-Q · filed 2022-05-16 | -$178.90K 10-Q · filed 2021-05-21 | -$3.42M derived: sum of 2 quarters · filed 2022-05-16 | -$4.55M derived: sum of 3 quarters · filed 2022-08-12 | -$5.20M derived: sum of 4 quarters · filed 2022-08-12 | |||
| 2020-12-31 | -$406.71K derived: 10-K 12 month − 10-Q/A 9 month · filed 2022-03-31 | -$1.54M derived: sum of 2 quarters · filed 2022-08-12 | -$2.19M derived: sum of 3 quarters · filed 2022-08-12 | -$2.27M 10-K · filed 2022-03-31 | -$598.62K 10-K · filed 2021-04-01 | |||
| 2020-09-30 | -$1.13M derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2022-08-12 | -$1.78M derived: sum of 2 quarters · filed 2022-08-12 | -$1.86M 10-Q/A · filed 2022-08-12 | -$371.56K 10-Q · filed 2020-11-16 | -$2.12M derived: sum of 4 quarters · filed 2022-08-12 | |||
| 2020-06-30 | -$651.84K derived: 10-Q/A 6 month − 10-Q 3 month · filed 2022-08-12 | -$728.27K 10-Q/A · filed 2022-08-12 | -$306.89K 10-Q · filed 2020-08-14 | -$990.35K derived: sum of 3 quarters · filed 2022-08-12 | -$1.04M derived: sum of 4 quarters · filed 2022-08-12 | |||
| 2020-03-31 | -$76.43K 10-Q · filed 2021-05-21 | -$338.51K derived: sum of 2 quarters · filed 2021-05-21 | -$390.82K derived: sum of 3 quarters · filed 2021-05-21 | -$571.47K derived: sum of 4 quarters · filed 2021-05-21 | ||||
| 2019-12-31 | -$262.07K derived: 10-K/A 12 month − 10-Q 9 month · filed 2021-05-14 | -$314.39K derived: sum of 2 quarters · filed 2021-05-14 | -$495.04K derived: sum of 3 quarters · filed 2021-05-14 | -$792.73K 10-K/A · filed 2021-05-14 | ||||
| 2019-09-30 | -$52.31K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | -$232.96K derived: sum of 2 quarters · filed 2020-11-16 | -$530.66K 10-Q · filed 2020-11-16 | -$601.54K derived: sum of 4 quarters · filed 2020-11-16 | ||||
| 2019-06-30 | -$180.65K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | -$478.34K 10-Q · filed 2020-08-14 | -$549.23K derived: sum of 3 quarters · filed 2020-08-14 | -$616.63K derived: sum of 4 quarters · filed 2020-08-14 | ||||
| 2019-03-31 | -$297.70K 10-Q · filed 2020-05-15 | -$368.58K derived: sum of 2 quarters · filed 2020-05-15 | -$435.98K derived: sum of 3 quarters · filed 2020-05-15 | -$573.07K derived: sum of 4 quarters · filed 2020-05-15 | ||||
| 2018-12-31 | -$70.88K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-30 | -$138.29K derived: sum of 2 quarters · filed 2020-03-30 | -$275.37K derived: sum of 3 quarters · filed 2020-03-30 | -$473.19K 10-K · filed 2020-03-30 | ||||
| 2018-09-30 | -$67.40K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | -$204.49K derived: sum of 2 quarters · filed 2019-11-14 | -$402.30K 10-Q · filed 2019-11-14 | -$30.00 10-Q · filed 2018-11-08 | ||||
| 2018-06-30 | -$137.08K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | -$334.90K 10-Q · filed 2019-08-14 | -$470.71K derived: sum of 3 quarters · filed 2019-08-14 | |||||
| 2018-03-31 | -$197.82K 10-Q · filed 2019-05-15 | -$333.62K derived: sum of 2 quarters · filed 2019-05-15 | ||||||
| 2017-12-31 | -$135.81K 10-K · filed 2019-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |